[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610415":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":35,"locations":43,"responsibleParty":99,"collaborators":11,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":11,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":11,"studyType":114,"phases":115,"briefSummary":118,"conditions":119,"keywords":11,"overallStatus":122,"whyStopped":11,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"EG 427","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients who received EG110A in a clinical study, regardless of dose","EXPERIMENTAL",null,[13,14,15],"Other: Urodynamics","Drug: EG110A","Other: Patient-reported Outcome",[17,22,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":11},"OTHER","Urodynamics","standardized local evaluation of urodynamic parameters",[9],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","EG110A","Patients already treated with EG110A",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"Patient-reported Outcome","assessment of participant's perception of the level of impairment in functioning and well-being associated with NDO symptoms",[9],[32],{"name":33,"affiliation":5,"role":34},"Cornelia Haag-Molkenteller, MD","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Sandrine Zourbas, Ph.D.","CONTACT","33 (0)625622802","szourbas@eg427.com",{"name":33,"role":38,"phone":11,"phoneExt":11,"email":42},"Cornelia@eg427.com",[44,60,73,86],{"facility":45,"status":11,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Rancho Los Amigos National Rehabilitation Center","Downey","California","90242","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-118.13257,33.94001,{"lat":55,"lon":54},[58],{"name":59,"role":38,"phone":11,"phoneExt":11,"email":11},"Evgeniy Kreydin, MD",{"facility":61,"status":11,"city":62,"state":63,"zip":64,"country":49,"countryCode":50,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"University of Michigan Rogel Cancer Center","Ann Arbor","Michigan","48109",{"type":52,"coordinates":66},[67,68],-83.74088,42.27756,{"lat":68,"lon":67},[71],{"name":72,"role":38,"phone":11,"phoneExt":11,"email":11},"John Stoffel, MD",{"facility":74,"status":11,"city":75,"state":76,"zip":77,"country":49,"countryCode":50,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Sidney Kimmel Medical College","Philadelphia","Pennsylvania","19107",{"type":52,"coordinates":79},[80,81],-75.16362,39.95238,{"lat":81,"lon":80},[84],{"name":85,"role":38,"phone":11,"phoneExt":11,"email":11},"Patrick Shenot, MD",{"facility":87,"status":11,"city":88,"state":89,"zip":90,"country":49,"countryCode":50,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"UTHealth Houston \u002F TIRR Memorial Hermann","Houston","Texas","77030",{"type":52,"coordinates":92},[93,94],-95.36327,29.76328,{"lat":94,"lon":93},[97],{"name":98,"role":38,"phone":11,"phoneExt":11,"email":11},"Argyrios Stampas, MD",{"type":100,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610415","phase-1-long-term-follow-up-study-of-patients-who-received-eg110a-a-non-replicative-herpes-simplex-virus-1-derived-gene-therapy-100610415",false,"NCT07227285","Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy","Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Expressing a Transgene Encoding the Light Chain of Botulinum Toxin F","Inclusion Criteria:\n\n\\- All participants who received at least one dose\u002Finjection of EG110A in Study EG110A-001-01 and have prematurely discontinued or completed that study.\n\nExclusion Criteria:\n\n* Participant plans to participate in another investigational gene therapy study\n* Participant has an uncontrolled intercurrent illness, any disorder, or current substance abuse that would limit compliance with study requirements in the opinion of the investigator","ALL","18 Years","75 Years",{"count":112,"type":113},16,"ESTIMATED","INTERVENTIONAL",[116,117],"PHASE1","PHASE2","The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose\u002Finjection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.",[120,121],"Urinary Bladder, Overactive","Spinal Cord Injury","NOT_YET_RECRUITING","2025-11-10",{"date":125,"type":126},"2025-11-12","ACTUAL",{"date":128,"type":113},"2026-04",{"date":130,"type":113},"2031-04",{"name":5,"class":6},4]